Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with relapsing-remitting multiple sclerosis (a form of MS with flare-ups and periods of recovery) according to 2024 diagnostic guidelines.
- People whose MS symptoms first appeared less than 10 years ago.
- People whose MS has shown signs of activity in the last 24 months, such as a relapse or new or growing lesions visible on MRI scans compared to a previous MRI taken within the last 24 months (plus or minus 3 months).
- People currently taking a first-line MS medication (such as interferon, glatiramer acetate, teriflunomide, or fumarates) for less than 24 months.
- People who have had a standard MRI follow-up scan within the 90 days before joining the trial.
- People whose MS has been clinically stable for at least 30 days before joining.
- People already enrolled in certain MS observational studies or registries (such as OFSEP or PROMISE) may also be eligible.
- Women who could become pregnant must have a negative pregnancy test at the time of joining and must use an effective method of contraception throughout the trial.
- People who are able to attend all scheduled trial visits.
- People who have signed a consent form agreeing to take part.
- People who are covered by a health insurance plan.
Who may not be able to join:
- Women who are pregnant or breastfeeding.
- People who are unable to have brain and/or spinal cord MRI scans.
- People who are not willing to have monthly blood draws.
- People currently taking higher-intensity MS treatments, including medications such as natalizumab, ocrelizumab, alemtuzumab, cladribine, or similar drugs.
- People who have had a relapse within the 6 months before joining.
- People whose most recent MRI (within 3 months before joining) showed actively inflamed lesions (known as contrast-enhancing lesions).
- People with progressive MS (a form of MS that worsens steadily rather than in flare-ups).
- People who are unable to sign a consent form.
- People for whom it is not possible to provide adequate information about the trial.
- People already taking part in another clinical treatment trial, or who are within a waiting period after a previous trial (based on how long the previous trial drug stays in the body).
- People under judicial protection or adults under legal guardianship.
- Women of reproductive potential who are not willing to use effective contraception for the duration of the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Eric Thouvenot, Centre Hospitalier Universitaire de Nīmes
Phone: 04 66 68 32 61
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to evidence of disease activity between groups; Time to evidence of disease activity between groups
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.